2 Best ASX Blue-Chip Stocks for Long Term Holding

Macquarie Group Limited and CSL Limited are two ASX blue-chip companies. Macquarie Group Limited is a global financial services provider and CSL Limited is a leading biotechnology company specializing in life-saving medicines, vaccines, and therapies for serious diseases.

CSL Limited (ASX: CSL)

CSL Limited (ASX: CSL),on 29 June 2026, announced an update on TAVNEOS (avacopan), an in-licensed therapy marketed by its CSL Vifor affiliates under licence in the European Union and European Economic Area The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion recommending the revocation of the EU marketing authorisation for TAVNEOS. This opinion follows CHMP’s review under Article 20 of the handling of datain the pivotal Phase 3 ADVOCATE clinical trial supporting the product’s approval. 

On 11 May 2026, CSL announced its Interim CEO 90-Day Review and Financial Update which ighlighted its strong market leadership, portfolio expansion supported by effective lifecycle management and successful R&D, ongoing operational efficiency improvements, and value generated from previous mergers and acquisitions. CSL maintained its capital allocation priorities, which include reinvesting in growth opportunities, maintaining a net debt to EBITDA leverage ratio of 1.5–2.0x, and returning surplus cash flows to shareholders. 

Outlook:

The company expects revenue of approximately $15.2 billion and NPATA (excluding restructuring costs and impairments) of around $3.1 billion, both on a constant currency basis. The revised outlook reflects a $300 million revenue impact from the normalisation of U.S. immunoglobulin channel inventory, a $200 million impact due to lower albumin market value in China despite stable volumes and increased market share, and an additional $150 million impact from the Middle East conflict, revised HEMGENIX growth, and increased competition in the iron business. 

Macquarie Group Limited (ASX: MQG)

Macquarie Group Limited (ASX: MQG), on 22 June 2026, announced a distribution of $1.6148 ., which is 35% franked. The ex-distribution date is 2 September 2026, the record date is 3 September 2026, and the distribution will be paid on 18 September 2026 .

On 8 May 2026, the company reported strong FY2026 financial results. Net operating income increased by 13% year on year to $19,477 million, while operating expenses rose 5% to $12,748 million. Net profit increased 30% to $4,847 million, and return on equity improved to 14.0%. 

Outlook:

APRA announced a proposal to align individual Level 3 banking non-operating holding companies (NOHCs), including the company, with the broader bank prudential framework and to phase out hybrid instruments. APRA also stated that it would engage with the relevant Level 3 banking NOHCs to facilitate a smooth transition during the phase-out of hybrid instruments. 

(Source: Company Announcements)